
Hong Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2383154/publications.pdf Version: 2024-02-01



HONCLU

#	Article	IF	CITATIONS
1	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
2	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. Clinical Science, 2022, 136, 771-785.	1.8	2
3	A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia. BioMed Research International, 2022, 2022, 1-24.	0.9	8
4	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. Journal of the National Cancer Institute, 2021, 113, 1396-1404.	3.0	56
5	Erythrocyte adenosine A2B receptor prevents cognitive and auditory dysfunction by promoting hypoxic and metabolic reprogramming. PLoS Biology, 2021, 19, e3001239.	2.6	11
6	A Bayesian network metaâ€enalysis of comparison of cancer therapeutic vaccines for melanoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1976-1986.	1.3	3
7	Profiling of immune features to predict immunotherapy efficacy. Innovation(China), 2021, 3, 100194.	5.2	13
8	Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss. FASEB Journal, 2020, 34, 15771-15787.	0.2	9
9	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell, 2020, 37, 324-339.e8.	7.7	126
10	Potent USP10/13 antagonist spautinâ€l suppresses melanoma growth via ROSâ€mediated DNA damage and exhibits synergy with cisplatin. Journal of Cellular and Molecular Medicine, 2020, 24, 4324-4340.	1.6	30
11	Sex-associated molecular differences for cancer immunotherapy. Nature Communications, 2020, 11, 1779.	5.8	144
12	Erythrocyte Adenosine A2B Receptor-Mediated AMPK Activation: A Missing Component Counteracting CKD by Promoting Oxygen Delivery. Journal of the American Society of Nephrology: JASN, 2019, 30, 1413-1424.	3.0	17
13	Role of purines in regulation of metabolic reprogramming. Purinergic Signalling, 2019, 15, 423-438.	1.1	27
14	Elevated ecto-5′-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell disease. Blood Advances, 2018, 2, 1957-1968.	2.5	14
15	Erythrocytes retain hypoxic adenosine response for faster acclimatization upon re-ascent. Nature Communications, 2017, 8, 14108.	5.8	81
16	Erythrocyte purinergic signaling components underlie hypoxia adaptation. Journal of Applied Physiology, 2017, 123, 951-956.	1.2	25
17	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Scientific Reports, 2017, 7, 15281.	1.6	47
18	Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease. Scientific Reports, 2016, 6, 29637.	1.6	65

Hong Liu

#	Article	IF	CITATIONS
19	Sustained Elevated Adenosine via ADORA2B Promotes Chronic Pain through Neuro-immune Interaction. Cell Reports, 2016, 16, 106-119.	2.9	61
20	Beneficial Role of Erythrocyte Adenosine A2B Receptor–Mediated AMP-Activated Protein Kinase Activation in High-Altitude Hypoxia. Circulation, 2016, 134, 405-421.	1.6	115
21	AltitudeOmics: Red Blood Cell Metabolic Adaptation to High Altitude Hypoxia. Journal of Proteome Research, 2016, 15, 3883-3895.	1.8	98
22	Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia. Nature Communications, 2016, 7, 12086.	5.8	163
23	Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. FASEB Journal, 2016, 30, 874-883.	0.2	38
24	Beneficial and detrimental role of adenosine signaling in diseases and therapy. Journal of Applied Physiology, 2015, 119, 1173-1182.	1.2	67
25	Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies. Tumor Biology, 2014, 35, 11727-11733.	0.8	14
26	Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1–Dependent and –Independent Mechanisms. Journal of Immunology, 2011, 187, 3003-3014.	0.4	311